A review of the clinical introduction of 4D particle therapy research concepts.

4D Treatment Workshop for Particle Therapy 4D dose reconstruction 4D imaging Adaptive workflows Intrafractional motion Motion management Particle therapy

Journal

Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 11 10 2023
revised: 12 12 2023
accepted: 04 01 2024
medline: 1 2 2024
pubmed: 1 2 2024
entrez: 1 2 2024
Statut: epublish

Résumé

Many 4D particle therapy research concepts have been recently translated into clinics, however, remaining substantial differences depend on the indication and institute-related aspects. This work aims to summarise current state-of-the-art 4D particle therapy technology and outline a roadmap for future research and developments. This review focused on the clinical implementation of 4D approaches for imaging, treatment planning, delivery and evaluation based on the 2021 and 2022 Available technological capabilities for motion surveillance and compensation determined the course of each 4D particle treatment. 4D motion management, delivery techniques and strategies including imaging were diverse and depended on many factors. These included aspects of motion amplitude, tumour location, as well as accelerator technology driving the necessity of centre-specific dosimetric validation. Novel methodologies for X-ray based image processing and MRI for real-time tumour tracking and motion management were shown to have a large potential for online and offline adaptation schemes compensating for potential anatomical changes over the treatment course. The latest research developments were dominated by particle imaging, artificial intelligence methods and FLASH adding another level of complexity but also opportunities in the context of 4D treatments. This review showed that the rapid technological advances in radiation oncology together with the available intrafractional motion management and adaptive strategies paved the way towards clinical implementation.

Sections du résumé

Background and purpose UNASSIGNED
Many 4D particle therapy research concepts have been recently translated into clinics, however, remaining substantial differences depend on the indication and institute-related aspects. This work aims to summarise current state-of-the-art 4D particle therapy technology and outline a roadmap for future research and developments.
Material and methods UNASSIGNED
This review focused on the clinical implementation of 4D approaches for imaging, treatment planning, delivery and evaluation based on the 2021 and 2022
Results UNASSIGNED
Available technological capabilities for motion surveillance and compensation determined the course of each 4D particle treatment. 4D motion management, delivery techniques and strategies including imaging were diverse and depended on many factors. These included aspects of motion amplitude, tumour location, as well as accelerator technology driving the necessity of centre-specific dosimetric validation. Novel methodologies for X-ray based image processing and MRI for real-time tumour tracking and motion management were shown to have a large potential for online and offline adaptation schemes compensating for potential anatomical changes over the treatment course. The latest research developments were dominated by particle imaging, artificial intelligence methods and FLASH adding another level of complexity but also opportunities in the context of 4D treatments.
Conclusion UNASSIGNED
This review showed that the rapid technological advances in radiation oncology together with the available intrafractional motion management and adaptive strategies paved the way towards clinical implementation.

Identifiants

pubmed: 38298885
doi: 10.1016/j.phro.2024.100535
pii: S2405-6316(24)00005-8
pmc: PMC10828898
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

100535

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Barbara Knäusl (B)

Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Gabriele Belotti (G)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milano, Italy.

Jenny Bertholet (J)

Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Juliane Daartz (J)

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Stella Flampouri (S)

Emory University, Radiation Oncology, Atlanta, USA.

Mischa Hoogeman (M)

Department of Medical Physics & Informatics, HollandPTC, Delft, The Netherlands.
Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands.

Antje C Knopf (AC)

Institut für Medizintechnik und Medizininformatik Hochschule für Life Sciences FHNW, Muttenz, Switzerland.

Haibo Lin (H)

New York Proton Center, New York, NY, USA.

Astrid Moerman (A)

Department of Medical Physics & Informatics, HollandPTC, Delft, The Netherlands.

Chiara Paganelli (C)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milano, Italy.

Antoni Rucinski (A)

Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krakow, Poland.

Reinhard Schulte (R)

Division of Biomedical Engineering Sciences, School of Medicine, Loma Linda University.

Shing Shimizu (S)

Department of Carbon Ion Radiotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.

Kristin Stützer (K)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany.

Xiaodong Zhang (X)

Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ye Zhang (Y)

Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Switzerland.

Katarzyna Czerska (K)

Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Switzerland.

Classifications MeSH